Exploiting Long Noncoding RNAs as Pharmacological Targets to Modulate Epigenetic Diseases

Yale J Biol Med. 2017 Mar 29;90(1):73-86. eCollection 2017 Mar.

Abstract

Long non-coding RNAs (lncRNAs) constitute the largest class of non-coding transcripts in the human genome. Results from next-generation sequencing and bioinformatics advances indicate that the human genome contains more non-coding RNA genes than protein-coding genes. Validated functions of lncRNAs suggest that they are master regulators of gene expression and often exert their influences via epigenetic mechanisms by modulating chromatin structure. Specific lncRNAs can regulate transcription in gene clusters. Since the functions of protein-coding genes in clusters are often tied to specific pathways, lncRNAs constitute attractive pharmacological targets. Here we review the current knowledge of lncRNA functions in human cells and their roles in disease processes. We also present forward-looking perspectives on how they might be manipulated pharmacologically for the treatment of a variety of human diseases, in which regulation of gene expression by epigenetic mechanisms plays a major role.

Keywords: drug target; epigenetics; gene expression; lncRNA; pharmacology.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Computational Biology
  • Epigenesis, Genetic / genetics*
  • Gene Expression Regulation / genetics
  • Humans
  • RNA, Long Noncoding / genetics*

Substances

  • RNA, Long Noncoding